626 related articles for article (PubMed ID: 36038913)
1. Recent advances in therapeutic strategies for triple-negative breast cancer.
Li Y; Zhang H; Merkher Y; Chen L; Liu N; Leonov S; Chen Y
J Hematol Oncol; 2022 Aug; 15(1):121. PubMed ID: 36038913
[TBL] [Abstract][Full Text] [Related]
2. An overview of triple-negative breast cancer.
Kumar P; Aggarwal R
Arch Gynecol Obstet; 2016 Feb; 293(2):247-69. PubMed ID: 26341644
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
4. Targeting triple-negative breast cancer: A clinical perspective.
Popovic LS; Matovina-Brko G; Popovic M; Punie K; Cvetanovic A; Lambertini M
Oncol Res; 2023; 31(3):221-238. PubMed ID: 37305385
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapeutic interventions of Triple Negative Breast Cancer.
Li Z; Qiu Y; Lu W; Jiang Y; Wang J
J Transl Med; 2018 May; 16(1):147. PubMed ID: 29848327
[TBL] [Abstract][Full Text] [Related]
6. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
[TBL] [Abstract][Full Text] [Related]
7. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?
Le Du F; Eckhardt BL; Lim B; Litton JK; Moulder S; Meric-Bernstam F; Gonzalez-Angulo AM; Ueno NT
Oncotarget; 2015 May; 6(15):12890-908. PubMed ID: 25973541
[TBL] [Abstract][Full Text] [Related]
8. Role of the androgen receptor in triple-negative breast cancer.
Rampurwala M; Wisinski KB; O'Regan R
Clin Adv Hematol Oncol; 2016 Mar; 14(3):186-93. PubMed ID: 27058032
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in targeted strategies for triple-negative breast cancer.
Zhu S; Wu Y; Song B; Yi M; Yan Y; Mei Q; Wu K
J Hematol Oncol; 2023 Aug; 16(1):100. PubMed ID: 37641116
[TBL] [Abstract][Full Text] [Related]
10. Triple Negative Breast Cancer: A Tale of Two Decades.
Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
[TBL] [Abstract][Full Text] [Related]
11. Triple negative breast cancer in Asia: An insider's view.
Wang C; Kar S; Lai X; Cai W; Arfuso F; Sethi G; Lobie PE; Goh BC; Lim LHK; Hartman M; Chan CW; Lee SC; Tan SH; Kumar AP
Cancer Treat Rev; 2018 Jan; 62():29-38. PubMed ID: 29154023
[TBL] [Abstract][Full Text] [Related]
12. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
13. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
[TBL] [Abstract][Full Text] [Related]
14. Research progress on immunotherapy in triple‑negative breast cancer (Review).
Zhang X; Ge X; Jiang T; Yang R; Li S
Int J Oncol; 2022 Aug; 61(2):. PubMed ID: 35762339
[TBL] [Abstract][Full Text] [Related]
15. Signaling Pathways and Natural Compounds in Triple-Negative Breast Cancer Cell Line.
Dewi C; Fristiohady A; Amalia R; Khairul Ikram NK; Ibrahim S; Muchtaridi M
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744786
[TBL] [Abstract][Full Text] [Related]
16. Immunological therapy: A novel thriving area for triple-negative breast cancer treatment.
Wang X; Qi Y; Kong X; Zhai J; Li Y; Song Y; Wang J; Feng X; Fang Y
Cancer Lett; 2019 Feb; 442():409-428. PubMed ID: 30419345
[TBL] [Abstract][Full Text] [Related]
17. Targeting Notch-Driven Cytokine Secretion: Novel Therapies for Triple Negative Breast Cancer.
Marini W; Wilson BE; Reedijk M
DNA Cell Biol; 2023 Feb; 42(2):73-81. PubMed ID: 36579947
[TBL] [Abstract][Full Text] [Related]
18. Targeted Therapies for Triple-Negative Breast Cancer.
Lyons TG
Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
[TBL] [Abstract][Full Text] [Related]
19. Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer.
Nath A; Mitra S; Mistry T; Pal R; Nasare VD
Med Oncol; 2021 Nov; 39(1):14. PubMed ID: 34812991
[TBL] [Abstract][Full Text] [Related]
20. CDKN2A-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in triple-negative breast cancer.
Cheng T; Wu Y; Liu Z; Yu Y; Sun S; Guo M; Sun B; Huang C
Front Immunol; 2022; 13():970950. PubMed ID: 36052076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]